This property gives LOXO-305 higher affinity and selectivity for BTK in addition to inhibition of the C481S mutant, although this is less relevant for MCL as it is for CLL as the C481S mutation rate is much lower in MCL as discussed previously. Here, BTK is linked to B-cell chronic lymphocytic leukemia.